Adrenocortical Carcinoma

Comprehensive Clinical Guide: Adrenocortical Carcinoma (ACC)

1. Comprehensive Introduction & Overview

Adrenocortical Carcinoma (ACC) is a rare, aggressive malignancy originating from the cortex of the adrenal gland. While adrenal tumors are relatively common—often discovered incidentally as "incidentalomas"—the vast majority are benign adrenocortical adenomas. ACC, conversely, represents a significant clinical challenge due to its propensity for local invasion, distant metastasis, and the complex hormonal syndromes it frequently induces.

Epidemiologically, ACC exhibits a bimodal age distribution, peaking in childhood and the fourth to fifth decades of life. It is notably more common in women than men. The prognosis remains poor for patients with advanced-stage disease, necessitating a multidisciplinary approach involving endocrinologists, surgical oncologists, medical oncologists, and pathologists.

2. Etiology and Pathophysiology

Molecular Mechanisms

The pathogenesis of ACC is characterized by a high degree of chromosomal instability and specific genetic mutations. Approximately 60% of sporadic ACC cases demonstrate somatic mutations in the TP53 tumor suppressor gene.

Key molecular drivers include:
* Wnt/β-catenin signaling pathway: Aberrant activation is observed in the majority of ACC cases.
* IGF2 Overexpression: The IGF2 gene (located on 11p15) is frequently overexpressed, acting as a potent mitogen for adrenocortical cells.
* Li-Fraumeni Syndrome: Germline TP53 mutations significantly elevate the lifetime risk of developing ACC.
* Beckwith-Wiedemann Syndrome: Associated with epigenetic abnormalities at the 11p15 locus, leading to IGF2 overexpression.

Histopathology

Microscopically, ACC is categorized using the Weiss System, which evaluates nine histological criteria to distinguish malignant from benign adrenocortical tumors. A score of 3 or higher is highly suggestive of malignancy.

3. Clinical Presentation and Indications

Hormonal Excess (Functional Tumors)

Approximately 60% of ACCs are "functional," meaning they secrete hormones. The clinical presentation depends on the specific hormone excess:
* Glucocorticoid Excess (Cushing’s Syndrome): Rapid onset of weight gain, moon facies, supraclavicular fat pads, striae, hypertension, and hyperglycemia.
* Androgen Excess (Virilization): Hirsutism, acne, clitoromegaly (in women), and deepening of the voice.
* Mineralocorticoid Excess (Conn’s Syndrome): Hypertension and hypokalemia (less common in ACC compared to adenomas).

Non-Functional Presentation

Non-functional tumors (approx. 40%) often present late due to mass effect. Symptoms include:
* Abdominal or flank pain.
* Palpable abdominal mass.
* Early satiety or nausea due to compression of adjacent organs.

4. Clinical Staging and Grading

Staging is critical for determining the therapeutic strategy. The ENSAT (European Network for the Study of Adrenal Tumors) staging system is the current gold standard.

ENSAT Staging System

5. Diagnostic Workup

A rigorous diagnostic protocol is mandatory to differentiate ACC from benign lesions and pheochromocytoma.

1. Biochemical Evaluation:
   • 24-hour urinary free cortisol or 1mg overnight dexamethasone suppression test.
   • Serum potassium and aldosterone/renin ratio.
   • Plasma metanephrines (to exclude pheochromocytoma).
   • DHEA-S and testosterone levels.
2. Imaging:
   • CT/MRI: High-resolution imaging to assess tumor size, heterogeneity, calcifications, and vascular invasion.
   • PET/CT (18F-FDG): Useful for assessing metabolic activity and staging distant disease.
3. Contraindication Alert: Fine-needle aspiration (FNA) is generally contraindicated in suspected ACC because it cannot reliably distinguish between adenoma and carcinoma and carries a risk of tumor seeding along the needle track.

6. Management and Prognosis

Surgical Intervention

Complete surgical resection (R0 resection) is the only potentially curative treatment. An open adrenalectomy is preferred over laparoscopic approaches in cases where malignancy is highly suspected to ensure adequate margins and prevent capsular rupture.

Adjuvant Therapy

• Mitotane: An adrenolytic agent that is the standard of care for adjuvant therapy in high-risk patients. It requires close monitoring of serum levels (target 14–20 mg/L) due to a narrow therapeutic index.
• Chemotherapy: For advanced/metastatic disease, the combination of etoposide, doxorubicin, and cisplatin (EDP) plus mitotane is the conventional regimen.

Long-term Prognosis

The 5-year survival rate varies significantly based on stage:
* Localized disease: 60–80%
* Metastatic disease: <15%

7. Risks and Complications

• Mitotane Toxicity: Common adverse effects include gastrointestinal distress (nausea, diarrhea), central nervous system toxicity (lethargy, vertigo), and adrenal insufficiency (necessitating glucocorticoid replacement).
• Surgical Complications: Hemorrhage, injury to the vena cava, and adrenal crisis post-operatively.
• Metastatic Spread: High risk of recurrence even after complete resection; requires lifelong surveillance.

8. Frequently Asked Questions (FAQ)

1. Is Adrenocortical Carcinoma common?
No, it is extremely rare, with an incidence of approximately 0.7–2 per million people per year.

2. Why is a biopsy not performed?
Biopsy carries the risk of tumor seeding and cannot reliably differentiate between benign and malignant cells in the adrenal cortex.

3. What is the role of the Weiss score?
The Weiss score is a standardized histological grading system used by pathologists to determine the malignancy of an adrenal tumor.

4. Can ACC be cured?
Localized ACC can be cured with complete surgical resection. However, recurrence rates are high, necessitating long-term follow-up.

5. What is Mitotane?
Mitotane is a derivative of the insecticide DDT that selectively destroys adrenal cortex cells. It is the only FDA-approved drug specifically for ACC.

6. Does cortisol production always indicate cancer?
No. Many benign adenomas produce excess cortisol. However, high levels of DHEA-S are more suggestive of malignancy.

7. How often should I get scans after surgery?
Typically, CT scans of the chest, abdomen, and pelvis are performed every 3 to 6 months for the first two years, then annually thereafter.

8. Are all adrenal tumors cancerous?
No, the vast majority of adrenal tumors found on imaging are benign adenomas.

9. What is the primary site of metastasis for ACC?
The liver and lungs are the most common sites of distant metastasis.

10. Is ACC hereditary?
While most cases are sporadic, ACC can be associated with hereditary syndromes like Li-Fraumeni, Lynch syndrome, and Beckwith-Wiedemann syndrome.

9. Conclusion

Adrenocortical Carcinoma remains a complex, high-stakes diagnosis. Success in patient outcomes is predicated on early detection, high-volume surgical expertise, and meticulous long-term oncological follow-up. As molecular profiling continues to evolve, targeted therapies may eventually augment or replace traditional cytotoxic regimens, offering hope for improved survival in patients with advanced-stage disease.

Disclaimer: This guide is intended for educational purposes for healthcare professionals and does not constitute medical advice. Clinical decisions should be based on institutional protocols and individual patient assessment.